Spontaneous miscarriage after intracytoplasmic sperm injection with frozen sperm of patients with testicular germ cell tumour Authors: Haru Hamada, Akifumi Ijuin, Tomonari Hayama, Naoki Tsuchiya, Sumiko Sueyoshi, Misaki Toda, Ai Miyakoshi, Mayuko Kurumizaka, Marina Saito, Yuki Oike, Hiroe Ueno, Shinnosuke Kuroda, Kazumi Takeshima, Teppei Takeshima, Shin Saito, Ryoko Asano, Taichi Mizushima, Yasushi Yumura, Hideya Sakakibara, Etsuko Miyagi, Miki Tanoshima, Mariko Murase Published: 2026 ABSTRACT AbstractObjectiveTo clarify the impact of chromosomal aberrations on the offspring of patients with testicular germ cell tumour (TGCT) by evaluating the outcomes of intracytoplasmic sperm injection (ICSI).Patients and MethodsUnder the ethical review of Yokohama City University, 12 patients with TGCT and 25 with non‐TGCT cancer who had cryopreserved sperm for ICSI for fertility preservation between 1 April 2014 and 31 March 2023 were enrolled. For 198 oocytes from the TGCT group, 480 oocytes from the non‐TGCT group, fertilisation, embryo viability, pregnancy, and spontaneous miscarriage rates were examined.ResultsFemales who received ICSI from patients with TGCT showed a significantly higher spontaneous miscarriage rate than those who received ICSI from patients with non‐TGCT cancer (43.8% vs 9.1%, respectively, P < 0.05), with no significant between‐group difference in the pregnancy rate. In the TGCT group, three cases of recurrent pregnancy loss and recurrent implantation failure were reported. The high spontaneous miscarriage rate in the TGCT group can be attributed to chromosomal abnormalities or DNA fragmentation in the sperm of patients with TGCT.ConclusionNatural conception may be an option for patients who have completed TGCT treatment and have adequate sperm. However, when semen parameters do not recover sufficiently, assisted reproductive technologies may be considered, including, where possible, the use of post‐treatment sperm not affected by TGCT rather than pre‐treatment sperm collected during tumour‐bearing state. In selected cases, pre‐implantation genetic testing for aneuploidy may also be considered.Keywords: intracytoplasmic sperm injection, cryopreservation, fertility preservation, sperm aneuploidy, spontaneous miscarriages, testicular germ cell tumour Abbreviations assisted reproductive technology germ cell neoplasia in situ intracytoplasmic sperm injection interquartile range in vitro fertilisation pre‐implantation genetic testing for aneuploidy recurrent implantation failure recurrent pregnancy loss testicular germ cell umour Introduction With medical advances emphasising the quality of life of cancer survivors, preservation of fertility has become one of the main concerns. Testicular cancer is the most common malignancy in males aged 15–40 years, accounting for ~1% of all male cancers and 5% of urological tumours globally [1]. Testicular germ cell tumour (TGCT) accounts for ~98% of all testicular cancers [2]. Racial differences have always been noted, with rates among young White men being >10‐times higher than those among Black or Asian men. However, increasing trends of TGCT have recently been reported among all ethnicities [3]. Several publications have reported an increase in the incidence of TGCT in industrialised countries in recent decades [3]. Recently, patients with TGCT have demonstrated remarkably high survival rates owing to advances in chemotherapy and radiotherapy. The impact of TGCT on fertility, as well as the risk of birth defects and spontaneous miscarriage, are some of the major concerns for survivors. Men with infertility are three times more likely to develop testicular cancer than normozoospermic men, suggesting shared aetiological factors, with TGCT being a key contributor [4]. A retrospective cohort study found that poor semen quality was associated with an increased risk of testicular cancer, likely owing to shared genetic and epigenetic abnormalities affecting gamete quality and cancer cell proliferation [5]. Previous studies have demonstrated that most patients with TGCT have reduced sperm count at the time of diagnosis (before any anticancer therapy), which deteriorates further during treatment [4, 6, 7]. The duration and severity of spermatogenic damage cannot be predicted as these depend on various factors, including the dose and duration of chemotherapy, testicular function before therapy, type of cancer, and other unknown factors [8]. Despite an early depression in spermatogenesis, the sperm count of most patients recovers within 1–2 years of treatment, with variable sperm counts in their ejaculated semen [9]; however, their fertility may not be restored. Even if the sperm count recovers, the sperm quality decreases after treatment [10]. Furthermore, Jensen et al. [11] were concerned about treatment‐induced deterioration of DNA quality and recommended sperm preservation before starting the treatment. Because of the potential mutagenic effects of chemotherapy and radiotherapy, the fertility of cryopreserved sperm collected during or after treatment, along with the safety status of pregnancies conceived with sperms whose spermatogenesis has been restored after treatment remain unknown [12]. Therefore in 2006, the American Society of Clinical Oncology strongly recommended sperm cryopreservation prior to treatment of malignant tumours, including TGCT, in males of reproductive age. Previous reports have revealed higher rates of sperm aneuploidy in patients with TGCT than in healthy male controls [6, 13]. The sperm aneuploidy rate is reported to be high before treatment [6, 7]. However, only a few studies have examined the pregnancy outcomes of couples who have a male partner with TGCT. A study of Swedish national registry data demonstrated that the risk of neonatal malformations, including aneuploidy, was 30% higher in pregnancies involving patients with TGCT than in pregnancies involving patients without TGCT. However, the risk was deemed negligible when assisted reproductive technology (ART) pregnancies were excluded [14]. To the best of our knowledge, no study has reported on pregnancy outcomes with cryopreserved sperm collected from male partners prior to TGCT treatment. To clarify the prognosis of ART pregnancies involving the sperm of patients with TGCT, we compared the intracytoplasmic sperm injection (ICSI) outcomes, eliminating spontaneous sperm competition, between patients with TGCT and those with non‐TGCT cancer as controls. By investigating the ICSI outcomes, we aimed to determine the developmental stages of the embryos derived from oocytes fertilised with sperm from patients with TGCT and whether TGCT increases the rate of neonatal malformations. Patients and Methods This single‐centre, retrospective study collected data from the medical records and infertility registry databases of our centre. Informed consent was obtained by the opt‐out method, which involved posting a detailed explanation of the study on our centre's website, including its purpose, methods, potential benefits, risks, and the participants’ rights to withdraw their data without any disadvantages. This method aligns with ethical guidelines for retrospective studies, where obtaining direct consent may not be feasible, while ensuring respect for participants’ autonomy. The study was approved by the Yokohama City University Ethics Committee (approval number F230800013) and conducted in line with the Declaration of Helsinki principles. Measures to protect confidentiality, such as anonymisation during data collection and analysis, were implemented throughout the study. The present study included couples whose male partner was diagnosed with TGCT or non‐TGCT malignancies and had cryopreserved ejaculated sperm for fertility preservation before primary starting anticancer therapy. The couples underwent ICSI with cryopreserved sperm at our hospital between 1 April 2014 and 31 March 2023. To avoid the effect of confounding factors, such as chemotherapy‐induced fertility decline, and ensure that the outcomes reflect baseline fertility prior to treatment, patients who already underwent chemotherapy were excluded. This study exclusively focused on patients with TGCTs originating only in the testes. Patients who cryopreserved their sperm after chemotherapy and had extragonadal germ cell tumours were excluded (Fig. 1). These patients were excluded to ensure homogeneity within the group and minimal variability related to tumour origin or metastatic spread. No patient with lymph node metastases was identified in the study population. Flowchart of participant selection. Clinical information was retrospectively collected from the medical records. The following characteristics were examined: female age at oocyte retrieval, male age at sperm cryopreservation, and presence and causes of female infertility. The main outcomes were the fertilisation rate, usable embryo rate (cryopreserved or transferred), clinical pregnancy rate after embryo transfer, and spontaneous miscarriage rate. These data were compared between the two groups: the TGCT group, which included males with TGCT and their female partners who underwent ICSI using their cryopreserved sperm; and the non‐TGCT malignancies group, which included males with a non‐TGCT malignancy and their female partners who underwent ICSI with their cryopreserved sperm. Semen parameters used for analysis were obtained before cancer treatment, at the time of sperm cryopreservation for fertility preservation. ICSI using cryopreserved sperm was performed in patients who developed azoospermia or showed worsened semen parameters after cancer treatment, as well as in couples who had insufficient time to wait for recovery of semen parameters or were unable to achieve pregnancy through natural conception. Embryo transfer characteristics were also analysed, including type of transfer (fresh or frozen), endometrial preparation, number of embryos transferred, and embryo stage. There were no significant differences between the TGCT and non‐TGCT groups in embryo transfer characteristics, including the proportion of fresh vs frozen embryo transfers, the use of artificial vs natural cycles, and the distribution of cleavage‐stage vs blastocyst transfers (for all comparisons, P > 0.05). Statistical analyses were conducted to evaluate the differences between the TGCT and non‐TGCT groups. Categorical variables, such as spontaneous miscarriage and clinical pregnancy rates, were analysed using Fisher's exact test, while continuous variables, including male age at sperm cryopreservation and female partner age, were analysed using the Mann–Whitney U test. We conducted logistic regression analysis to adjust for potential confounding variables such as female partner age and embryo quality. All statistical analyses were performed with EZR (Saitama Medical Center, Jichi Medical University, Saitama, Japan), a graphical user interface for R (The R Foundation for Statistical Computing, Vienna, Austria). This software is a modified version of the R commander designed to add statistical functions frequently used in biostatistics. Statistical significance was set at P < 0.05. Results During the study period of 10 years, 36 couples were enrolled. The treatment outcomes were compared between the TGCT (12 patients) and non‐TGCT groups (24 patients) (Table 1, Tables S1 and S2, Fig. 1). Of the 12 patients with TGCT, four had seminoma and eight had non‐seminomas. Of the 24 patients with non‐TGCT, 17 were diagnosed with malignant haematopoietic diseases, two with prostate cancer, two with lung cancer, and three with other cancers (Fig. 1). In both groups, all couples underwent ICSI using cryopreserved sperm obtained before chemotherapy. Table 1Clinical characteristics of the patients.CharacteristicTGCT groupNon‐TGCT group P Number of patients1224Male age at sperm cryopreservation, years, median (IQR)31.5 (29–34)37.0 (31–46)0.13Female age at oocyte retrieval, years, median (IQR)32.0 (31–34)35.0 (32–39)0.070Total sperm count, × 106, median (IQR)64.2 (37.4–80.5)62.4 (31.3–125.5)0.58Total motile sperm count, × 106, median (IQR)3.4 (2.8–25.8)15.51 (5.8–27.2)0.19Motile sperm rate, × 106, median (IQR)25.1 (6.7–36.3)30.1 (17.8–37.2)0.37Fertilisation rate, %, mean (SD)82.6 (16.9)76.2 (22.2)0.39Usable embryos rate, %, mean (SD)51.3 (18.9)58.5 (21.8)0.33Clinical pregnancy rate/embryo transfer, %42.127.60.14Spontaneous miscarriage rate/pregnancy, %43.89.50.024 Clinical characteristics of the patients. The median (interquartile range [IQR]) age of male patients at sperm cryopreservation was 31.5 (29–34) years in the TGCT group and 37.0 (31–46) years in the non‐TGCT group. The median (IQR) age of female partners was 32.0 (31–34) years in the TGCT group and 35.0 (32–39) years in the non‐TGCT group. There were no significant differences in the age of the male patients or their female partners in the TGCT and non‐TGCT groups (P > 0.05, Table 1, Fig. 2A,B). The median (IQR) total sperm count and motile sperm rate were 64.2 (37.4–80.5) × 106 and 25.1% (6.7–36.3%) in the TGCT group, and 62.4 (31.3–125.5) × 106 and 30.1% (17.8–37.2%) in the non‐TGCT group, respectively, with no significant differences in either count between the two groups (P > 0.05, Table 1, Fig. 2C,D). Comparison of patient characteristics in TGCT and non‐TGCT groups. (A) Male age at time of sperm cryopreservation. (B) Female age at oocyte retrieval. (C) Total sperm count. (D) Motile sperm rate. No significant differences were observed in all parameters. The horizontal line within the box indicates the median. The box represents the IQR. Whiskers extend to the minimum and maximum values excluding outliers. The mean fertilisation rates were 82.6% and 77.3% in the TGCT and non‐TGCT groups, respectively. Although the fertilisation rate appeared to be higher in the TGCT group, the difference was not statistically significant (P > 0.05, Table 1, Fig. 3A). The quality of sperm from patients with TGCT may not significantly impair their ability to fertilise oocytes under ICSI conditions. The mean usable embryo rates were 51.3% and 61.0% in the TGCT and non‐TGCT groups, respectively (P > 0.05, Table 1, Fig. 3B). Comparison of ICSI outcomes in TGCT and non‐TGCT groups. (A) Fertilisation rate. (B) Usable embryo rate. (C) Clinical pregnancy rate. (D) Spontaneous miscarriage rate. Spontaneous miscarriage was significantly higher for TGCT than non‐TGCT. *P < 0.05. ns, not significant. The bars in these figures represent the SDs. The number of clinical pregnancy and pregnancy rates per embryo transfer were 16/38 (42.1%) and 21/75 (28.0%) in the TGCT and non‐TGCT groups, respectively, with no significant differences observed between the two groups (P > 0.05, Fig. 3C). However, the spontaneous miscarriage rate per pregnancy was significantly higher in the TGCT group (seven of 16 [43.8%]) than in the non‐TGCT group (two of 21 [9.5%]) (P < 0.05, Fig. 3D). Recurrent pregnancy loss (RPL), defined as two or more spontaneous miscarriages, occurred in three of 12 couples in the TGCT group and in none of the couples in the non‐TGCT group. Five couples in the TGCT group and seven in the non‐TGCT group had infants without any congenital defect. There were no significant differences in pregnancy outcomes observed between the four patients with seminoma and eight patients with non‐seminoma. To explore the significantly higher spontaneous miscarriage rate in the TGCT group, multivariate regression analysis, adjusted for potential confounding variables such as female partner age and usable embryo rate, was conducted. After adjusting for these factors, the spontaneous miscarriage rate in the TGCT group remained significantly higher, with an adjusted odds ratio of 11.8 (95% CI 1.48–93.7, P = 0.02). This finding suggests that factors related to TGCT itself may contribute to the increased risk of spontaneous miscarriage. In Japan, pre‐implantation genetic testing for aneuploidy (PGT‐A) has only been performed for recurrent implantation failure (RIF) or RPL since 2019, albeit on a limited basis, in accordance with the regulations of the Japanese Society of Obstetrics and Gynaecology. In this study, one patient each in the TGCT and non‐TGCT groups had undergone PGT‐A (Table S3); only one blastocyst was obtained with the sperm of the patient with TGCT, whereas four blastocysts were obtained with the sperm of the patient with a non‐TGCT malignancy. The blastocyst obtained from the patient with TGCT who had undergone PGT‐A was found to have trisomy 22. Of the four blastocysts obtained from the patient with a non‐TGCT malignancy, two embryos were euploid, one embryo had low‐frequent mosaicism, and another embryo had complex aneuploidy. Discussion To the best of our knowledge, this is the first study to demonstrate that pregnancy outcomes after ICSI performed using sperm from patients with TGCT. We found that ICSI for TGCT was associated with high rates of spontaneous miscarriage. Testicular germ cell tumour is believed to originate from primordial germ cells that fail to normally differentiate into pre‐spermatogenic cells during early fetal life [15]. These primordial germ cells with altered maturation, accumulate in the ductus deferens and form a pre‐invasive neoplastic lesion called germ cell neoplasia in situ (GCNIS). The current aetiological model of TGCT is based on the hypothesis that GCNIS cells begin to proliferate at puberty and eventually acquire malignant potential [15]. GCNIS is considered a finding associated with testicular hypofunction and is often incidentally diagnosed in males with infertility conditions, such as oligospermia [16, 17]. A high rate of sperm aneuploidy has been reported in the sperm of patients with oligospermia [18]. Multiple studies have demonstrated a high rate of aneuploidy in the sperm of patients with GCNIS [6, 13]; the GCNIS precursors may be involved in the spermatogenesis of aneuploid spermatozoa. As mentioned above, patients with TGCT have been shown to have high sperm aneuploidy rates, but, to our knowledge, only one study [14] has described the effect of TGCT on the offspring. The study found that the offspring of men with TGCT had a 30% higher rate of malformations than those of healthy men [14]. In our study, we examined the ICSI outcomes of patients with TGCT and non‐TGCT malignancies and compared their ART pregnancy outcomes. There were no significant differences in the fertilisation or usable embryo rates between the groups. Additionally, malformations in infants were not observed in either group. However, the spontaneous miscarriage rate was high in the TGCT group. These findings suggest that the high rates of abnormalities in the sperm of patients from the TGCT group was reflected in the high spontaneous miscarriage rate with the use of ART and the high rates of malformations in the offspring. Further, the malformation rate decreased when ART pregnancies were excluded. While the reason behind this finding was not well defined, we considered the following possible reasons. First, patients with TGCT whose partners require ICSI may have poorer spermatogenesis and a higher percentage of aneuploid sperm in their total sperm than those with TGCT with adequate semen quality for a natural (non‐ART) pregnancy. This trend is consistent with the fact that GCNIS, a possible aetiology of TGCT, is associated with impaired spermatogenesis. Patients with resolution of GCNIS after treatment may conceive naturally with a low spontaneous miscarriage rate owing to recovered semen function and a reduced percentage of aneuploid sperm. Second, in cases of fertilisation without ICSI, including in vitro fertilisation (IVF), the rates of aneuploid sperm in patients with TGCT and the general population would not differ because of sperm selection; however, when using ICSI, an artificial sperm selection method that weakens or eliminates natural sperm competition, the TGCT group would have a high malformation and spontaneous miscarriage rate. Although we cannot elucidate this difference owing to the small number of cases involved in the present analysis, we speculate that, in cases of artificial insemination, the high ratio of aneuploid sperm due to TGCT directly leads to a high ratio of aneuploid pregnancies, resulting in a high spontaneous miscarriage rate. Comparisons with other malignancies further underscore the unique reproductive risks associated with TGCT. In patients with haematological cancers, for example, chemotherapy‐induced sperm abnormalities, including DNA fragmentation and aneuploidy, often improve after treatment cessation [19]. In contrast, patients with TGCT frequently exhibit sperm abnormalities even before starting treatment, highlighting the distinct pathophysiological mechanisms underlying their reproductive risks. Previous studies have reported that semen quality may already be impaired in patients with TGCT before treatment [4, 6, 7]. Furthermore, semen parameters may further decline after cancer treatment, although recovery is often observed within 1–2 years [9]. In the present study, cryopreserved sperm obtained before cancer treatment was used for ICSI; therefore, post‐treatment semen data were not consistently available for analysis. In the case of natural conception or IVF, a natural sperm competition mechanism is involved. Conversely, in ICSI, the embryologist selects sperm with favourable morphology or motility instead of implementing the natural sperm competition mechanism. While these two factors are critical indicators of sperm quality, other factors, such as oxidative stress, epigenetic alterations, and reactive oxygen species, may also influence sperm function and embryonic development. Oxidative stress is known to damage nuclear and mitochondrial DNA, impairing sperm motility and increasing the risk of embryonic abnormalities [20]. Even if a skilled embryologist selects the sperm, visual selection based on morphology and motility may not guarantee the selection of functionally good sperm, resulting in the inadvertent selection of sperm with numerous chromosomal abnormalities. A large‐scale study demonstrated that ICSI did not increase the risk of congenital abnormalities compared with IVF [21]. Another large‐scale study revealed a statistically significant but modest increase in the risk of birth defects in the children of males with a history of cancer, independent of the mode of pregnancy [22]. No statistically significant difference in birth defects was reported between ART and spontaneous conception [23]. However, a 1.37‐fold increase in congenital anomalies has been reported with ART [24], and a British study reported a significantly higher number of congenital anomalies in children born to oligozoospermic fathers who had undergone ICSI than in those born to non‐oligozoospermic fathers [25]. Whether the cause of aneuploidy is sperm or oocytes, PGT‐A is an effective tool for examining embryos without transferring them to the uterus. In the present study, although PGT‐A was performed in limited cases, aneuploid embryos were found in both groups. However, patients with RPL existed only in TGCT group, and the rate of spontaneous miscarriage was high in the TGCT group, possibly attributed to embryo aneuploidy caused by sperm aneuploidy. PGT‐A may be effective in identifying the cause of RIF and RPL in couples with TGCT as well as in reducing their risk. However, PGT‐A is invasive to the embryo and also includes cost issues, access issues (the need for specialised facilities), and the possibility of euploid embryos being discarded for mosaicism or technical errors. While PGT‐A is not currently recommended as a routine procedure for all patients with TGCT, its application in patients with a history of RIF or RPL should be considered. In ICSI using cryopreserved sperm for fertility preservation, the sperm abnormality rate was higher in the TGCT group than in the non‐TGCT malignancy groups. Sperm selection in ICSI is challenging due to the difficulty in identifying chromosomal abnormalities and DNA fragmentation based on sperm motility and morphology. Furthermore, the selection of abnormal sperm does not affect the fertilisation or usable embryo rates (cryopreserved or transferred) but rather affects the rates of spontaneous miscarriage. Therefore, patients with TGCT should be informed about the risks associated with pregnancy and about how PGT‐A may reduce those risks. Because of decreased sperm counts and increased DNA fragmentation and aneuploidy due to cancer treatment, sperm cryopreservation prior to treatment is recommended for patients with cancer [26]. However, the effects of sperm aneuploidy and fragmentation after cancer treatment are reduced in ~2 years [13]. On the other hand, sperm abnormalities are frequently observed in patients with TGCT even prior to treatment [22, 26]. In our study, spontaneous miscarriage was more frequent in pregnancies that occurred after ICSI with cryopreserved sperm than in pregnancies that occurred before TGCT treatment. Patients who receive treatment for TGCT are no less likely to further children than the general male population [27]. Although some people may be concerned about the effects of chemotherapy, if sperm analysis results show improvements and natural conception is expected, natural conception may be an option. This study has some limitations. First, the single‐centre design may limit the generalisability of findings to other clinical practices and demographics. Second, the small sample size in the TGCT group reduced the statistical power and the robustness of the conclusions. Third, selection bias may have influenced results, as patients choosing sperm cryopreservation may have had different levels of baseline fertility or cancer severity compared to those who did not. The non‐TGCT group comprised patients with various types of malignancies and therefore represented a heterogeneous population, which may limit the generalisability of our findings. A control group consisting of men without cancer, such as post‐vasectomy ICSI patients or men with proven fertility, might provide a more appropriate comparison in future studies. Because the number of patients with TGCT was limited, subgroup analysis comparing patients with normal and abnormal semen parameters was not feasible in the present study. Future studies with larger sample sizes, including multi‐institutional collaborations, may help to further clarify the relationship between semen parameters and reproductive outcomes in patients with TGCT. Finally, the study period spanned 9 years (2014–2023), during which laboratory procedures and clinical practices may have evolved, potentially influencing the outcomes. In conclusion, the spontaneous miscarriage rate was significantly higher in the TGCT group than in the non‐TGCT group. Chromosomal abnormalities or DNA fragmentation in the sperm of patients with TGCT may manifest as spontaneous miscarriage when ICSI is performed. Natural conception may be an option for patients who have completed TGCT treatment and have adequate sperm. However, even when semen parameters do not recover sufficiently to permit natural conception, the use of post‐treatment sperm not affected by TGCT for ART may be considered, rather than the use of sperm potentially affected by TGCT prior to treatment. When cryopreserved sperm collected before treatment is used, PGT‐A may be considered in selected cases. The benefits of PGT‐A in patients with TGCT cannot be confirmed through single‐centre analyses, as ICSI using fertility‐preserving frozen sperm in these patients is rarely performed. Future large‐multicentre studies or government‐based investigations, as well as longitudinal follow‐up studies of offspring, are needed to accurately evaluate fertility preservation strategies and reproductive outcomes of patients with TGCT. Disclosure of Interests The authors have nothing to report. Ethics Approval and Consent to Participate This study was approved under the ethics committee of Yokohama City University (approval number: F230800013). Informed consent was obtained from all the patients. Funding Information The authors have nothing to report. Supporting information Table S1. Patients’ characteristics and ICSI outcomes of the TGCT group. Table S2. Patients’ characteristics and ICSI outcomes of non‐TGCT group. Table S3. Patients’ characteristic data and PGT‐A outcomes of TGCT and non‐TGCT groups. Acknowledgements The authors would like to thank all the workers (embryologists, clinicians, technicians, statisticians) who directly or indirectly contributed to the creation and analysis of the data presented here. H.H., A.I. and T.H. contributed equally to this work and share first authorship. Data Availability Statement All data we examined in this study were presented in article, figures, tables and Supplemental information. References Associated Data Supplementary Materials Table S1. Patients’ characteristics and ICSI outcomes of the TGCT group. Table S2. Patients’ characteristics and ICSI outcomes of non‐TGCT group. Table S3. Patients’ characteristic data and PGT‐A outcomes of TGCT and non‐TGCT groups. Data Availability Statement All data we examined in this study were presented in article, figures, tables and Supplemental information.